
Fauci on COVID Drugs, Vaccines and Getting Back to Normal
The U.S.’s top infectious disease specialist describes a new Biden administration program to develop and test antivirals—and what he’s most worried about as the nation reopens...
The U.S.’s top infectious disease specialist describes a new Biden administration program to develop and test antivirals—and what he’s most worried about as the nation reopens...
A genomic revolution is poised to cure sickle cell and other genetic diseases
Developing pills that block the novel coronavirus has been challenging. A new Biden administration program aims to boost the effort
Studies suggest mixing vaccines provokes potent immune responses, but scientists want answers on real-world efficacy and rare side effects
This revolutionary gene-editing system has taken science by storm.
Researchers have begun to crack the code of protein structure, allowing them to remake, well, everything
Scientists are searching for explanations to disappointing final-stage trial results. These insights could help guide the future development of mRNA vaccines
Fee-for-service models, such as that of the U.S., and single-payer models, such as those of the U.K. and Canada, both have significant flaws—but Singapore may have found a workable compromise...
After transitioning in 1917, Alan L. Hart helped alter medical history
Many scientists say there is not enough evidence that Biogen’s aducanumab is an effective therapy for the disease
It’s one of the most challenging organs to re-create
A pediatric infectious disease expert answers questions about whether the vaccine is safe and why children need it
Preliminary results from a trial of more than 600 people are the first to show the benefits of combining different vaccines
People older than 80 who waited 11 to 12 weeks for their second jab had higher peak antibody levels than did those who waited only three weeks
Pfizer-BioNTech vaccine approval is younger teens’ shot at freedom
The illegal substance—paired with intensive therapy and hard work—dramatically improves PTSD symptoms
Hopes were high for drugs designed to lower levels of a mutant protein, but development has stalled
The development from the Biden administration draws cheers from public health researchers and ire from drugmakers
Clear messaging and transparency are vital, say some experts on risk assessment and decision-making
Next-generation COVID-19 vaccines will not only tackle different versions of the virus but will provide solutions across the world at a fraction of the cost
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account